See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Stock Markets
Social Media
Tariffs
UK Economy
Taxes
Soccer
Donald Trump
Education
Senate
Artificial Intelligence
Published • loading... • Updated

FDA Accepts, Grants Priority Review Designation for Bayer's msNRA for Patients with Heart Failure

Summary by DAIC
Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) that met primary cardiovascular endpoint in a Phase III study investigating patients with heart failure with mildly reduced or preserved ejection fraction.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
DAICDAIC

FDA Accepts, Grants Priority Review Designation for Bayer's msNRA for Patients with Heart Failure

Kerendia (finerenone) is a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) that met primary cardiovascular endpoint in a Phase III study investigating patients with heart failure with mildly reduced or preserved ejection fraction.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

DAIC broke the news in on Wednesday, March 26, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States

United States

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal